Shuchi Mittal
About Shuchi Mittal
Shuchi Mittal is a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, with extensive experience in neuroscience research and drug development.
Title and Current Role
Shuchi Mittal is currently working as a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, United States. She started this role in November 2021 and has been contributing to the company's research and development initiatives in this capacity.
Previous Positions at Bristol Myers Squibb
Before her current role, Shuchi Mittal has held multiple positions at Bristol Myers Squibb. She worked as a Senior Scientist for 10 months in 2021 and as a Scientist in Neuroscience TRC from 2019 to 2020. Her work has primarily focused on neuroscience research within the company.
Experience at Celgene and Simmons University
Shuchi Mittal has also worked as a Scientist in Neuroscience and Imaging at Celgene from 2018 to 2019. Additionally, she served as an Adjunct Faculty in Biology at Simmons University from 2016 to 2019, where she was involved in teaching and mentoring students.
Harvard Medical School Research Positions
Shuchi Mittal held significant research positions at Harvard Medical School, including being a Senior Research Fellow from 2015 to 2018 and a Postdoctoral Research Fellow from 2010 to 2015. During her tenure, she focused on advancing her research expertise and contributing to the academic community.
Educational Background
Shuchi Mittal completed her Ph.D. in Biological Sciences and Bioengineering from the Indian Institute of Technology, Kanpur, where she studied from 2002 to 2009. She also holds a Master's degree in Life Sciences from CSJM University, Kanpur, earned from 2000 to 2002, and a Bachelor's degree in Zoology, Botany, and Chemistry from Rohilkhand University, Bareilly, completed from 1997 to 2000.
Skills and Specializations
Shuchi Mittal is skilled in developing high-throughput drug screening assays specifically for brain diseases. She is also proficient in identifying novel drug targets and advancing lead compounds for clinical trials, which has been a consistent focus throughout her career.